The Diagnosis Map: From PSA to Treatment
If you just received your diagnosis, you are probably holding results from several tests that feel disconnected from each other. In practice, they usually follow a logical sequence ā not necessarily in this exact order, since every case is individualized:
- PSA elevated or trending upward on follow-up ā assessed alongside age, prostate size, and other factors
- Multiparametric MRI (mpMRI) of the prostate ā each suspicious focus scored with PI-RADS (1 to 5)
- Suspicious finding ā targeted (MRI Fusion) and often systematic biopsy
- Histology ā Gleason score mapped to an ISUP Grade Group (1 to 5)
- Clinical exam, imaging, and histology together ā TNM stage (local extent, lymph nodes, metastases)
- In selected higher-risk cases or suspected spread ā PSMA PET/CT
- All of the above combined ā a risk group classification
- Risk group + age + overall health + your priorities ā treatment strategy discussion
This "map" is conceptual, not a mandatory test-by-test checklist for every patient. Your own urologist decides which steps are needed in your specific case.
Quick Reference: What Each Term Means at a Glance
Before going into detail, here is a snapshot of what each term you likely heard in the clinic actually describes:
PSA
A blood biomarker. Reflects a trend, not a diagnosis on its own ā it also rises in benign conditions.
PSA Density
PSA divided by prostate volume. Helps assess whether a PSA rise is "explained" by the size of the gland.
PI-RADS
A 1ā5 score for an mpMRI finding. Expresses the likelihood of clinically significant cancer ā it is not a diagnosis.
Gleason Score
Describes how differentiated or atypical the cells look in a biopsy sample, as the sum of two growth patterns (e.g. 3+4).
ISUP Grade Group
A simplified 1ā5 classification that groups Gleason combinations into a single, more easily comparable scale.
TNM Stage
Describes local extent (T), lymph node involvement (N), and any metastases (M) ā clinically or pathologically.
PSMA PET/CT
Whole-body molecular imaging, mainly used for staging in selected higher-risk cases or suspected recurrence.
Just Received the Diagnosis: What Is Worth Doing First
It is completely normal for the first days after a positive biopsy to feel like you have too many numbers and terms to process at once. You do not need to understand all of it on the same day.
- Ask your urologist to explain your pathology result in plain language, not just the numbers
- Keep copies of your test results (mpMRI, biopsy, PSA) ā you will need them for every future opinion
- Give yourself time before deciding anything; prostate cancer rarely requires a treatment decision within days
- If something is unclear, ask for a further explanation or a second opinion ā this is completely normal and accepted
PSA After Diagnosis: What Changes
Before diagnosis, PSA is used mainly to decide whether further work-up is needed. After diagnosis, its role changes: it becomes one of the factors that make up your risk group, and later, after treatment, it becomes a monitoring tool.
A higher PSA at diagnosis tends to correlate with a greater likelihood of more extensive disease, but it does not predict on its own the Gleason/ISUP grade or the stage ā some patients have relatively low PSA with more aggressive histology, and vice versa.
PSA Density: Why Prostate Size Matters
PSA density is calculated by dividing PSA by prostate volume (as estimated on MRI or ultrasound). The logic is simple: a larger prostate "normally" produces more PSA, without that meaning cancer. A higher PSA density raises clinical suspicion, especially combined with PI-RADS 3, while a lower PSA density can support the idea that a borderline picture is more likely due to benign enlargement than cancer. There is no single, universally accepted PSA density cutoff that decides biopsy or treatment on its own ā it is used as one more factor in the overall picture.
PI-RADS 3, 4, or 5: What It Means After a Positive Biopsy
If you already have a positive biopsy, the PI-RADS score from your initial MRI has already "done its job" ā it guided where the biopsy targeted. At this point, the histology result itself (Gleason/ISUP) carries more weight than a retrospective interpretation of the PI-RADS score. PI-RADS remains useful, however, for:
- identifying additional foci that may not yet have been biopsied
- assessing local extent of disease (e.g. possible extracapsular extension)
- planning follow-up in patients on active surveillance
If you want a detailed, step-by-step explanation of the PI-RADS scale, see our complete PI-RADS guide.
Gleason Score: How to Read 3+4 or 4+3
The pathologist examines the biopsy sample and recognizes growth patterns of the glandular cells, graded from 3 (better differentiated) to 5 (worse differentiated). The Gleason score is the sum of the most common pattern (first number) and the second most common (second number).
3+4=7 and 4+3=7 have the same sum but are not clinically identical: in 3+4, the predominant pattern is the more favourable one (3), while in 4+3 the less favourable pattern (4) predominates. This is exactly why the ISUP system was created ā to avoid the confusion that "7 equals 7" means the same thing in every case.
ISUP Grade Groups 1ā5: The Table That Unified Gleason
In 2014, the International Society of Urological Pathology (ISUP) proposed a simplified 1-to-5 scale, precisely because the same Gleason sum could correspond to a different prognosis. This produced the five grade groups:
ISUP 1
Gleason ā¤6 (3+3). The most favourable histological pattern.
ISUP 2
Gleason 3+4=7, with the more favourable pattern (3) predominating.
ISUP 3
Gleason 4+3=7, with the less favourable pattern (4) predominating.
ISUP 4
Gleason 8 (4+4, 3+5, or 5+3).
ISUP 5
Gleason 9ā10 (4+5, 5+4, or 5+5). The least favourable histological pattern.
TNM Stage: cT, N, M, and the Difference Between Clinical and Pathological Stage
The TNM system describes three dimensions of the disease:
- T (Tumor) ā local extent within or beyond the prostate
- N (Nodes) ā lymph node involvement (N0 = no, N1 = yes)
- M (Metastasis) ā distant spread (M0 = no, M1 = yes)
An important distinction: clinical stage (cT) is based on digital rectal exam, imaging, and biopsy before any surgery, while pathological stage (pT) is only available after surgical removal, once the pathologist examines the entire surgical specimen. The two can differ ā a cT2 (apparently confined) case may ultimately turn out to be pT3 (with extracapsular extension) after surgery, without this meaning the initial assessment was "wrong" ā it simply reflects a different level of information accuracy.
When PSMA PET/CT Is Needed
PSMA PET/CT is not performed in every newly diagnosed patient. It is usually discussed in selected scenarios: initial staging in higher-risk disease (where the likelihood of nodal or distant disease is not negligible), or restaging in the case of biochemical recurrence after treatment. It does not replace mpMRI or biopsy at initial diagnosis, and a negative result does not fully exclude microscopic disease.
Risk Groups: Low, Intermediate, and High
The European Association of Urology (EAU) guidelines combine PSA, ISUP Grade Group, and clinical stage into three main risk groups, meant to guide ā not dictate ā the treatment discussion:
- Low risk ā generally PSA <10 ng/mL, ISUP 1, and cT1āT2a
- Intermediate risk ā does not meet low- or high-risk criteria (e.g. PSA 10ā20, or ISUP 2ā3, or cT2b)
- High risk ā generally PSA >20 ng/mL, or ISUP 4ā5, or cT2cāT3
Other classification systems, such as the National Comprehensive Cancer Network (NCCN) in the United States, use similar but not always identical cutoffs, and may include additional subcategories. If you see a different wording in another source, this is usually because a different classification system is being used ā ask your urologist which one applies in your case.
How It All Fits Together: Three Hypothetical Examples
The following are purely hypothetical examples for educational purposes ā they are not a treatment prescription for any specific case. Every real patient is assessed individually.
Example A
PSA 5.2 ng/mL, PI-RADS 3, ISUP 1, cT1c. A profile that typically falls into the low-risk category ā active surveillance is often discussed as one of the options.
Example B
PSA 8.7 ng/mL, PI-RADS 4, ISUP 2ā3, cT2b. An intermediate-risk profile ā the discussion usually involves a broader range of treatment options to weigh.
Example C
PSA 24 ng/mL, PI-RADS 5, ISUP 4ā5, cT3a. A higher-risk profile ā often involves further staging (e.g. PSMA PET/CT) before the final decision.
How Treatment Is Chosen: The Factors That Matter
- Risk group (low, intermediate, high)
- Age and life expectancy
- Coexisting conditions and overall physical fitness
- Pre-existing urinary continence and erectile function
- Your personal priorities and concerns (e.g. attitude toward surveillance versus immediate treatment)
- Availability and expertise in each treatment approach at the center you choose
Active Surveillance: When It Is Discussed
Active surveillance is a structured monitoring strategy ā with regular PSA, repeat MRI, and, where indicated, repeat biopsy ā that avoids or delays immediate treatment in selected patients with low-risk, and in some cases favourable intermediate-risk, disease. It does not mean "doing nothing" ā it means close, scheduled monitoring with clear criteria for when a change in strategy would be recommended. Suitability is fully individualized by your urologist.
Radical Prostatectomy: When It Is Discussed
Surgical removal of the prostate ā robotic radical prostatectomy or, alternatively, laparoscopic radical prostatectomy ā is often discussed in patients with localized intermediate- or high-risk disease, and selectively in low-risk disease when preferred by the patient over surveillance. If you have already scheduled or undergone this surgery, you may also be interested in our guide After Robotic Radical Prostatectomy: The First 90 Days.
Radiotherapy: When It Is Discussed
Radiotherapy (external beam or brachytherapy, depending on the case) is one of the established treatment options across several risk levels, often with comparable long-term oncologic outcomes to surgery in selected patients ā the choice between the two approaches depends more on factors such as age, coexisting conditions, and personal preference than on a universal "better" option. A radiation oncologist is usually involved in discussing this option together with your urologist.
Combined Treatments and Hormone Therapy
In patients with intermediate- or high-risk disease, radiotherapy is often combined with a limited or extended course of hormone therapy (androgen deprivation therapy) to enhance the outcome. In selected higher-risk cases, a combination of surgery with adjuvant therapy may also be discussed. The exact strategy is fully individualized and decided together with your urologist and, where radiotherapy is involved, a radiation oncologist.
No Single Number Decides Your Treatment
It is easy, seeing a PSA number or a PI-RADS 4, to feel that "everything has already been decided." In reality, no single value ā not PSA, not PI-RADS, not Gleason/ISUP, not stage on its own ā determines treatment. The decision comes from combining all of these with your age, overall health, and your own priorities, through discussion with your urologist ā not from an algorithm on paper.
10 Questions Worth Asking Your Urologist
- What is my ISUP Grade Group and what does it mean in practice?
- Which risk group do I fall into, and according to which system (EAU, NCCN)?
- Do I need a PSMA PET/CT in my case, and why or why not?
- Which treatment options are realistic for me today?
- Am I a candidate for active surveillance?
- What are the likely continence and erectile function risks for each option?
- How urgent is this decision ā do I have time to seek a second opinion?
- How will my PSA be monitored after whichever treatment I choose?
- What is your experience, or the center's experience, with the treatment you are recommending?
- What would change the recommendation if something on imaging or biopsy changes in the future?
Second Opinions and Follow-Up in Rhodes
A recent prostate cancer diagnosis often comes with a need to discuss specialized imaging and histology findings without having to travel off the island for every step. At our clinic in Rhodes, we can discuss your mpMRI, PI-RADS score, pathology result, and stage, plan ā where indicated ā a targeted MRI Fusion biopsy or transrectal biopsy, and guide you toward the appropriate next test or treatment option for your specific case.